iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

GSK Pharma records PAT of Rs 1,219 crore in Q4 FY22

17 May 2022 , 09:56 AM

Net sales during the quarter increased by 8.9% YoY to Rs 809.63 crore. Profit before tax (PBT) (before exceptional items) from continuing operations for the fourth quarter was Rs 178 crore, recording a growth of 6% YoY. GSK Pharmas consolidated net profit surged to Rs 1,694.72 crore in FY22 from Rs 358.15 crore in FY21. Net sales rose by 12% to Rs 3,278.03 crore in FY22 over FY21. PBT (before exceptional) from continuing operations for the year at Rs 767 crore, registering a growth of 22% YoY. EBITDA margin improved by 3%. Sridhar Venkatesh, managing director, GlaxoSmithKline Pharmaceuticals, said, ?During the year, our General Medicines portfolio continued to gain market share in their respective categories. Our execution focus on key brands helped us revitalise growth particularly in the anti-infectives, dermatology and pain segments. While our vaccines business was impacted due to low vaccination rates, many of our key brands gained share in a declining market, fuelled by disciplined execution. We continue to maintain market leadership in the private vaccines market. During the quarter, we concluded the transfer of Iodex and Ostocalcium brands to GlaxoSmithKline Asia, as part of GSK plcs plans to create two world class companies in pharmaceuticals and consumer healthcare.? The board recommended a dividend of Rs 90 per share which includes a special dividend of Rs 60 per share. GlaxoSmithKline Pharmaceuticals is a subsidiary of GlaxoSmithKline plc, one of the worlds leading research-based pharmaceutical and healthcare companies. The scrip rose 0.93% to currently trade at Rs 1528.20 on the BSE. Powered by Capital Market – Live News

Related Tags

  • capital market
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.